Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/S0140-6736(17)32094-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Application of Artificial Intelligence to Analyze Data from Randomized Controlled Trials: An Example from DECAAF-II.
Heart Rhythm
January 2025
Cardiology Department, Tulane University School of Medicine, New Orleans, Louisiana, United States. Electronic address:
Background: Causal machine learning (ML) provides an efficient way of identifying heterogeneous treatment effect groups from hundreds of possible combinations, especially for randomized trial data.
Objective: The aim of this paper is to illustrate the potential of applying causal ML on the DECAAF II trial data. We proposed a causal ML model to predict the treatment response heterogeneity.
Arrhythmogenic Right Ventricular Cardiomyopathy: the importance of biventricular strain in risk-stratification.
Am J Cardiol
January 2025
Department of Cardiology, Heart Lung Center, Leiden University Medical Center, Albinusdreef 2, 2333, ZA, The Netherlands. Electronic address:
Despite arrhythmogenic right ventricular cardiomyopathy (ARVC) being predominantly a right ventricular (RV) disease, concomitant left ventricular (LV) involvement has been recognized. ARVC is diagnosed by the RV-centric 2010 Task Force Criteria(TFC) using routine echocardiography, but previous studies have suggested that strain imaging may be more sensitive to detect RV and LV dysfunction. No data however are available regarding the additional value of combining biventricular strain for risk stratification.
View Article and Find Full Text PDFSimplifying coronary artery disease risk stratification: development and validation of a questionnaire-based alternative comparable to clinical risk tools.
EBioMedicine
December 2024
Department of Endocrinology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands.
Background: Coronary artery disease (CAD) comprises one of the leading causes of morbidity and mortality both in the European population and globally. All established clinical risk stratification scores and models require blood lipids and physical measurements. The latest reports of the European Commission suggest that attracting health professionals to collect these data can be challenging, both from a logistic and cost perspective, which limits the usefulness of established models and makes them unsuitable for population-wide screening in resource-limited settings, i.
View Article and Find Full Text PDFBackground: The prevalence and impact of right ventricular dysfunction (RVD) in degenerative mitral regurgitation (DMR) is unknown. We aimed to determine whether RVD assessed by echocardiography in routine clinical practice is independently associated with mortality in patients with DMR.
Methods And Results: We used data from the MIDA-Q (Mitral Regurgitation International DAtabase-Quantitative) registry, which included patients with isolated DMR due to mitral valve prolapse from January 2003 to January 2020 from 5 tertiary centers across North America, Europe, and the Middle East.
Timing of Aortic Valve Intervention in the Management of Aortic Stenosis.
JACC Cardiovasc Interv
November 2024
Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. Electronic address:
Aortic stenosis (AS) affects about 12% of people aged ≥75 years. Accumulating evidence on the prognostic importance of cardiac damage in patients with asymptomatic and less than severe AS supports the proposition of advancing aortic valve replacement (AVR) to earlier disease stages. Potential benefits of earlier treatment, including prevention of cardiac damage progression and reduced cardiovascular hospitalizations, need to be balanced against the earlier procedural risk and subsequent lifetime management after AVR.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!